An isoxazoline compound with optical activity is shown in the formula (I). The compound of the formula (I) has excellent herbicidal activity, can be used for weeding pre- and post-emergence, and can also be used for soil treatment. The compound of the formula (I) can effectively control various broad-leaved weeds, grass weeds and Cyperaceae weeds, and can control various resistant weeds, such as glyphosate-resistant weeds. The excellent weeding effect can be obtained at a low dose. The compound has good safety to crops such as corn, wheat, rice, soybean and sugar beet. The compound can be used as a selective herbicide in crop fields in agriculture, and can also be used as a non-selective herbicide in non-cultivated land, fallow land, woodland, orchards and ridges.

##STR00001##

An isoxazoline compound with optical activity is shown in the formula (I). The compound of the formula (I) has excellent herbicidal activity, can be used for weeding pre- and post-emergence, and can also be used for soil treatment. The compound of the formula (I) can effectively control various broad-leaved weeds, grass weeds and Cyperaceae weeds, and can control various resistant weeds, such as glyphosate-resistant weeds. The excellent weeding effect can be obtained at a low dose. The compound has good safety to crops such as corn, wheat, rice, soybean and sugar beet. The compound can be used as a selective herbicide in crop fields in agriculture, and can also be used as a non-selective herbicide in non-cultivated land, fallow land, woodland, orchards and ridges.

##STR00001##

The present invention provides methods for treating malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising aN-hydroxy-4-((4-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)benzamide.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. ##STR00001##

The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. ##STR00001##

A photochromic compound including a core skeletal structure represented by the following Formula (I), ##STR00001## wherein D is oxygen or sulfur; E is oxygen, sulfur, or NR.sup.2′; a is 0 or 1; R.sup.1 is hydrogen, or substituted or unsubstituted alkyl; R.sup.2 and R.sup.2′ are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; and the photochromic compound is a thermally reversible photochromic compound.

A photochromic compound including a core skeletal structure represented by the following Formula (I), ##STR00001## wherein D is oxygen or sulfur; E is oxygen, sulfur, or NR.sup.2′; a is 0 or 1; R.sup.1 is hydrogen, or substituted or unsubstituted alkyl; R.sup.2 and R.sup.2′ are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; and the photochromic compound is a thermally reversible photochromic compound.

An organic electroluminescence device includes an anode, a cathode, and an emitting layer disposed between the anode and the cathode. The emitting layer comprises a delayed fluorescent compound M2 having at least one deuterium atom and a compound M3 having at least one deuterium atom. A singlet energy S.sub.1(M2) of the compound M2 and a singlet energy S.sub.1(M3) of the compound M3 satisfy the relationship S.sub.1(M3)>S.sub.1(M2).